Financing Capital Expenditures and M&A through a Convertible Bond Issue
First written in FY2019-Q2. 1 of 3 entries say "Advanced", first in FY2019-Q3. Latest entry: FY2024-Q2.
20 other companies' latest entry also says "Achieved".
- FY2024-Q2AchievedAnnual report
「All remaining outstanding value of the '2024 Euro-yen convertible bonds with share acquisition rights' issued by the company on 18 April 2019 was exercised in full after the end of the third-quarter consolidated accounting period and by the exercise deadline of 4 April 2024.」
The remaining ¥3,540 million of the 2024 convertible bonds was exercised in full by 4 April 2024, completing the exercise of the convertible bonds used to fund capital expenditures and M&A. - FY2019-Q3AdvancedAnnual report
「The convertible bonds with share acquisition rights issued under the Companies Act during the third-quarter accounting period were as follows: 2024 Euro-yen convertible bonds with share acquisition rights. Balance of bonds with share acquisition rights (¥ thousands): 12,060,000.」
The company disclosed the specific terms of the 2024 Euro-yen convertible bonds with share acquisition rights issued on 18 April 2019: an outstanding balance of ¥12,060 million, a conversion price of ¥3,350 per share, and an exercise period from 7 May 2019 to 4 April 2024. - FY2019-Q2First statedAnnual report
「The approximately ¥12 billion in net proceeds from the issuance of these bonds with share acquisition rights will be used as follows: ① Approximately ¥8 billion is scheduled to be allocated to capital expenditures in the Human Infrastructure Business to expand and improve production capacity. ② Approximately ¥2 billion will be allocated by December 2019 to M&A and investments aimed at expanding the business scope under the keywords 'Global Medical (Healthcare) Agri.'」
The company announced plans to issue 2024 Euro-yen convertible bonds with share acquisition rights and allocate approximately ¥12 billion in net proceeds to capital expenditures of approximately ¥8 billion and M&A and investments of approximately ¥2 billion in the global medical, healthcare and agri sectors, among other uses.